Savara Stock

Savara EV/EBIT

The EV/EBIT (Enterprise Value to EBIT) of Savara (SVRA) as of Aug 20, 2026 is -8.53. In the previous year, EV/EBIT (Enterprise Value to EBIT) was -10.21 — a change of -16.47% (higher).

EV/EBIT

-8.53

YoY

-16.47%

Last updated:

EV/EBIT (Enterprise Value to EBIT) of Savara is 2026 -8.53 . EV/EBIT (Enterprise Value to EBIT) of Savara was 2025 -10.21 . It decreases by -16.47% higher compared to the previous year.

The Savara EV/EBIT history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

PRICE-TO-EBIT
Date
PRICE-TO-EBIT
Jan 1, 2019
-2.48 base
Jan 1, 2020
-1.44 base
Jan 1, 2021
-4.65 base
Jan 1, 2022
-6.10 base
Jan 1, 2023
-14.09 base
Jan 1, 2024
-5.90 base
Jan 1, 2025
-10.85 base
Jan 1, 2026 (e)
-10.87 base
YEARPRICE-TO-EBIT
2026 est -10.87
2025 -10.85
2024 -5.90
2023 -14.09
2022 -6.10
2021 -4.65
2020 -1.44
2019 -2.48
2018 -0.40
2017 -1.36
2016 -
2015 -
2014 -
2013 -
2012 -
2011 -
2010 -
2009 -
2008 -
2007 -
2006 -
Access this data via the Eulerpool API

Savara Valuation

Details

Historical Valuation Multiples

Price-to-Earnings Ratio (P/E)

The P/E ratio divides Savara's share price by its earnings per share. It tells you how many years of current earnings you are "paying for" when you buy the stock. A P/E of 20 means you pay $20 for every $1 of annual earnings. The S&P 500 historically trades at an average P/E of roughly 15–17. A P/E significantly above that may signal high growth expectations; one below may indicate undervaluation — or declining business quality.

Price-to-Sales Ratio (P/S)

The P/S ratio divides market capitalization by total revenue. Unlike the P/E ratio, it works even for companies that are not yet profitable, making it essential for evaluating high-growth firms. A P/S below 1.0 may indicate undervaluation, while ratios above 10 are typically reserved for fast-growing tech or SaaS companies with high expected future margins.

Price-to-EBIT Ratio

This ratio relates Savara's market price to its operating earnings, excluding the effects of debt structure and tax jurisdiction. It is particularly useful for comparing companies across different countries or with different levels of leverage, because it focuses purely on operational profitability. Lower values suggest cheaper operational earnings.

How to Use This Chart

This chart plots Savara's valuation multiples over time. Compare the current P/E, P/S, and P/EBIT to their own historical averages — if the current ratio is well below the multi-year average, the stock may be relatively cheap compared to its own track record. Combine this with industry comparisons: a P/E that looks high in absolute terms may be justified if Savara grows earnings faster than its peers.

Savara Stock analysis

What does Savara do? Savara Inc is a US biotechnology company specializing in the development and commercialization of therapies for rare respiratory diseases. The company was founded in 2007 and is headquartered in Austin, Texas. Savara initially focused on treating cystic fibrosis, a genetic disease that can cause severe lung problems. The company developed an innovative therapy based on the use of liposomes, tiny bubbles that can deliver medication directly to the lungs. This method was considered promising and received orphan drug status from the FDA, meaning it is intended for the treatment of rare diseases. However, due to high costs associated with developing and approving a new medication for cystic fibrosis, Savara decided to redefine its goals and focus on other rare respiratory diseases. The company's business model is based on identifying promising therapy approaches for these diseases and developing them into approvable medications. Savara collaborates closely with leading experts and scientists in the field of respiratory diseases. Its main therapy areas include cystic fibrosis, pulmonary fibrosis, and rare lung diseases. Savara has a special focus on developing liposome-based therapies, which have the potential to target the affected areas in the lungs and enhance the effects of other medications. Currently, the company offers three products: - AeroVanc: A liposome-based inhaled antibiotic used to treat cystic fibrosis-induced chronic lung infections. AeroVanc is the first FDA-approved medication in Savara's history. - Molgradex: A recombinant human granulocyte-macrophage colony-stimulating factor (GM-CSF) being developed for the treatment of autoimmune pulmonary alveolitis (also known as extrinsic allergic alveolitis). - AVAIL: A liposome-based inhaled antibiotic currently in Phase II of clinical development, being developed to treat non-tuberculous mycobacterial (NTM) lung infections. Savara has also formed partnerships with other companies and organizations to advance its research and development. Partners include the Cystic Fibrosis Foundation, the National Institutes of Health (NIH), and the European Respiratory Society. In summary, Savara Inc is a biotechnology company focused on developing therapies for rare respiratory diseases. The company has developed a promising technology platform and collaborates closely with leading experts and scientists in the field. Savara has a range of products on the market, including the first FDA-approved medication in the company's history. Savara is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Savara stock

EV/EBIT (Enterprise Value to EBIT) of Savara is -8.53 in 2026.

EV/EBIT (Enterprise Value to EBIT) of Savara changed from -10.21 to -8.53, representing a -16.47% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of EV/EBIT (Enterprise Value to EBIT) Savara since 2006 – with annual values, charts, and detailed analysis.

The EV/EBIT ratio measures a company's enterprise value relative to its operating earnings. It accounts for debt, making it useful for comparing companies with different capital structures.

EV/EBIT = Enterprise Value / Earnings Before Interest and Taxes

To evaluate EV/EBIT (Enterprise Value to EBIT)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for EV/EBIT (Enterprise Value to EBIT).

A 'good' varies by industry and company stage. On Eulerpool, you can compare EV/EBIT (Enterprise Value to EBIT)'s Savara with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

Valuation — Savara

All Key Metrics — Savara